- Stocks
- Healthcare
- NASDAQ: SUPN

Price (delayed)

$27.66

Market cap

$1.47B

P/E Ratio

14.56

Dividend/share

N/A

EPS

$1.9

Enterprise value

$1.65B

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for

Supernus Pharmaceuticals's revenue has increased by 35% YoY and by 2.6% from the previous quarter

The gross profit is up by 22% YoY

The stock's price to earnings (P/E) is 24% more than its last 4 quarters average of 11.9 but 20% less than its 5-year quarterly average of 18.5

The quick ratio has contracted by 10% from the previous quarter but it has grown by 3.8% YoY

The EPS has declined by 16% year-on-year and by 10% since the previous quarter

The company's net income fell by 15% YoY and by 10% QoQ

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: http://www.supernus.com

What are the main financial stats of SUPN

Market
Valuations
Earnings

Shares outstanding

53.15M

Market cap

$1.47B

Enterprise value

$1.65B

Price to earnings (P/E)

14.56

Price to book (P/B)

1.87

Price to sales (P/S)

2.57

EV/EBIT

10.44

EV/EBITDA

8.95

EV/Sales

2.89

Revenue

$570.95M

EBIT

$158.32M

EBITDA

$184.63M

Free cash flow

$118.12M

Per share
Balance sheet
Liquidity

EPS

$1.9

Free cash flow per share

$2.23

Book value per share

$14.82

Revenue per share

$10.77

TBVPS

$21.55

Total assets

$1.57B

Total liabilities

$787.48M

Debt

$406.53M

Equity

$785.58M

Working capital

$355.8M

Debt to equity

0.52

Current ratio

2.26

Quick ratio

1.93

Net debt/EBITDA

0.99

Margins
Efficiency
Dividend

EBITDA margin

32.3%

Gross margin

86%

Net margin

17.5%

Operating margin

24.1%

Return on assets

6.6%

Return on equity

13.4%

Return on invested capital

16.4%

Return on capital employed

12.3%

Return on sales

27.7%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Supernus Pharmaceuticals stock price performed over time

Intraday

-1.07%

1 week

1.47%

1 month

4.46%

1 year

33.11%

YTD

9.94%

QTD

-10.17%

How have Supernus Pharmaceuticals's revenue and profit performed over time

Revenue

$570.95M

Gross profit

$491.05M

Operating income

$137.72M

Net income

$100.19M

Gross margin

86%

Net margin

17.5%

The net margin is down by 37% year-on-year and by 13% since the previous quarter

Supernus Pharmaceuticals's revenue has increased by 35% YoY and by 2.6% from the previous quarter

The company's operating margin fell by 34% YoY and by 15% QoQ

The gross profit is up by 22% YoY

What is Supernus Pharmaceuticals's growth rate over time

What is Supernus Pharmaceuticals stock price valuation

P/E

14.56

P/B

1.87

P/S

2.57

EV/EBIT

10.44

EV/EBITDA

8.95

EV/Sales

2.89

The stock's price to earnings (P/E) is 24% more than its last 4 quarters average of 11.9 but 20% less than its 5-year quarterly average of 18.5

The EPS has declined by 16% year-on-year and by 10% since the previous quarter

SUPN's price to book (P/B) is 60% less than its 5-year quarterly average of 4.7 but 5% more than its last 4 quarters average of 1.8

Supernus Pharmaceuticals's equity has increased by 18% YoY and by 4.1% QoQ

The P/S is 48% below the 5-year quarterly average of 5.0 but 4% above the last 4 quarters average of 2.5

Supernus Pharmaceuticals's revenue has increased by 35% YoY and by 2.6% from the previous quarter

How efficient is Supernus Pharmaceuticals business performance

The return on sales has declined by 35% year-on-year and by 12% since the previous quarter

The company's return on equity fell by 31% YoY and by 14% QoQ

The return on assets has declined by 31% year-on-year and by 11% since the previous quarter

SUPN's return on invested capital is down by 12% since the previous quarter

What is SUPN's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for SUPN.

How did Supernus Pharmaceuticals financials performed over time

Supernus Pharmaceuticals's total assets is 100% higher than its total liabilities

The quick ratio has contracted by 10% from the previous quarter but it has grown by 3.8% YoY

SUPN's current ratio is up by 9% year-on-year but it is down by 7% since the previous quarter

The debt is 48% smaller than the equity

Supernus Pharmaceuticals's equity has increased by 18% YoY and by 4.1% QoQ

Supernus Pharmaceuticals's debt to equity has decreased by 16% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.